Filtered By:
Management: Healthcare Costs

This page shows you your search results in order of relevance. This is page number 8.

Order by Relevance | Date

Total 274 results found since Jan 2013.

Continuation with apixaban treatment is associated with lower risk for hospitalization and medical costs among elderly patients.
Conclusion: Elderly patients with NVAF in the U.S. who continued with apixaban treatment had a lower risk of MB-related hospitalization and lower MB- and stroke/SE-related medical costs compared to patients who switched to another OAC. PMID: 31120309 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - May 25, 2019 Category: Research Tags: Curr Med Res Opin Source Type: research

Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery.
CONCLUSIONS: Prophylaxis to prevent atrial fibrillation after cardiac surgery with any of the studied pharmacological or non-pharmacological interventions may be favored because of its reduction in the rate of atrial fibrillation, decrease in the length of stay and cost of hospital treatment and a possible decrease in the rate of stroke. However, this review is limited by the quality of the available data and heterogeneity between the included studies. Selection of appropriate interventions may depend on the individual patient situation and should take into consideration adverse effects and the cost associated with each ap...
Source: Cochrane Database of Systematic Reviews - March 2, 2013 Category: Journals (General) Authors: Arsenault KA, Yusuf AM, Crystal E, Healey JS, Morillo CA, Nair GM, Whitlock RP Tags: Cochrane Database Syst Rev Source Type: research

Outcomes in atrial fibrillation patients on combined warfarin & antiarrhythmic therapy
Conclusions: Allowing for differences in prescribing practice, AF/AFL patients treated with W+A are at higher risk of stroke and arterial embolism, and have higher healthcare use and costs, than patients receiving W+OAAD.
Source: International Journal of Cardiology - February 15, 2012 Category: Cardiology Authors: Annie Guérin, Jay Lin, Mehul Jhaveri, Eric Q. Wu, Andrew P. Yu, Martin Cloutier, Genevieve Gauthier, Joseph S. Alpert Tags: Original Articles Source Type: research

On National Wear Red Day, Let's Empower Women To Know Their Numbers To Help Reduce Heart Disease
Today is National Wear Red Day, an opportunity to splash this vibrant color into your wardrobe as a declaration of your support for women with heart disease and stroke. Doing so will link you in solidarity with Americans everywhere, including TV personalities across the networks and around the country. The tribute even extends to buildings and landmarks that will be bathed in red light. We hope each glimpse is a reminder of the toll that heart disease takes, not just on the victims but also on the survivors left without a mother or a daughter, a wife or a friend, a colleague or a neighbor, or any other key roles in our liv...
Source: Healthy Living - The Huffington Post - February 3, 2017 Category: Consumer Health News Source Type: news

Comparative effectiveness, safety, and costs of rivaroxaban and warfarin among morbidly obese patients with atrial fibrillation
ConclusionsMorbidly obese AF patients treated with rivaroxaban had comparable risk of ischemic stroke/systemic embolism and major bleeding as those treated with warfarin, but lower healthcare resource utilization and costs.
Source: American Heart Journal - February 21, 2019 Category: Cardiology Source Type: research

One-Year Costs Associated With the Veterans Affairs National TeleStroke Program
The objective of this study was to examine healthcare costs for patients with stroke who sought care before and after implementation of the US Department of Veterans Affairs National TeleStroke Program (NTSP).
Source: Value in Health - March 25, 2022 Category: International Medicine & Public Health Authors: Todd H. Wagner, Lena Schoemaker, Elizabeth Gehlert, Richard E. Nelson, Katherine Murphy, Sharyl Martini, Glenn D. Graham, Prasanthi Govindarajan, Linda S. Williams Tags: Themed Section Source Type: research

Effectiveness and Safety of Direct Oral Anticoagulants Among Patients with Non-valvular Atrial Fibrillation and Multimorbidity
ConclusionPatients with NVAF and  ≥ 6 comorbid conditions had significantly different risks for stroke/SE and MB when comparing DOACs to DOACs, and different healthcare expenses. This study's results may be useful for evaluating the risk–benefit ratio of DOAC use in patients with NVAF and multimorbidity.
Source: Advances in Therapy - December 17, 2022 Category: Drugs & Pharmacology Source Type: research

Impact of diabetes‐related complications on healthcare costs: new results from the UK Prospective Diabetes Study
ConclusionsDiabetic complications are associated with substantial immediate and long‐term healthcare costs. Our comprehensive new estimates of these costs, derived from detailed recent UK Prospective Diabetes Study post‐trial data, should aid researchers and health policy analyses.This article is protected by copyright. All rights reserved.
Source: Diabetic Medicine - November 29, 2014 Category: Endocrinology Authors: M. L. Alva, A. Gray, B. Mihaylova, J. Leal, R. R. Holman Tags: Research Article Source Type: research

The impact of diabetes‐related complications on healthcare costs: new results from the UKPDS (UKPDS 84)
ConclusionsDiabetic complications are associated with substantial immediate and long‐term healthcare costs. Our comprehensive new estimates of these costs, derived from detailed recent UK Prospective Diabetes Study post‐trial data, should aid researchers and health policy analyses.This article is protected by copyright. All rights reserved.
Source: Diabetic Medicine - November 29, 2014 Category: Endocrinology Authors: M. L. Alva, A. Gray, B. Mihaylova, J. Leal, R. R. Holman Tags: Research Article Source Type: research

Abstract 146: Clinical and Economic Consequences of Statin Intolerance in the U.S.: Results from an Integrated Health System Session Title: Poster Session I
Conclusion: While the majority of SI patients were on a statin, SI patients demonstrate a higher risk of some cardiovascular events; incur higher healthcare costs; and difficulty reaching LDL-C goals compared to patients without SI. Alternative treatment strategies are needed to better serve this at-risk patient population.
Source: Circulation: Cardiovascular Quality and Outcomes - April 29, 2015 Category: Cardiology Authors: Sanchez, R. J., Graham, J. H., Evans, M. A., Mallya, U. G., Panaccio, M. P., Steinhubl, S. R. Tags: Session Title: Poster Session I Source Type: research

Clinical and Economic Outcomes among Elderly Myocardial Infarction Survivors in the United States
ConclusionsRisks of mortality and cardiovascular events remain high in a Medicare population surviving >1 year after a MI. Continuing healthcare costs are doubled over pre‐MI levels up to five years after an MI. Secondary prevention measures beyond the acute post‐MI period may be indicated to reduce risk and cost in this chronic disease phase.This article is protected by copyright. All rights reserved.
Source: Cardiovascular Therapeutics - July 31, 2016 Category: Cardiology Authors: Erru Yang, Michael Stokes, Saga Johansson, Carl Mellstr öm, Elizabeth Magnuson, David J. Cohen, Phillip Hunt Tags: Original Research Article Source Type: research

Screening for undiagnosed atrial fibrillation.
Authors: Sandhu RK, Healey JS Abstract INTRODUCTION: Atrial fibrillation (AF) is a condition of global importance and it is associated with significant morbidity, mortality and healthcare costs. A considerable proportion of patients with AF are asymptomatic and stroke may be the first clinical manifestation of their AF diagnosis. AF screening provides an opportunity to identify patients with undetected AF prior to suffering a devastating complication. Areas covered: This review will provide a rationale for AF screening; summarize AF screening methods, studies and economic analyses; evaluate AF as a condition meetin...
Source: Expert Review of Cardiovascular Therapy - July 4, 2018 Category: Cardiology Tags: Expert Rev Cardiovasc Ther Source Type: research

Temporal trends in anticoagulation use and clinical outcomes among medicare beneficiaries with non-valvular atrial fibrillation
ConclusionsThe proportions of patients with non-valvular atrial fibrillation who were not prescribed an oral anticoagulant decreased but remained high. We observed an increase in direct oral anticoagulant use that coincided with decreased incidence of clinical outcomes as well as decreasing total healthcare costs.
Source: Journal of Thrombosis and Thrombolysis - August 2, 2023 Category: Hematology Source Type: research

Abstract 250: Economic Burden of Mortality and Cardiovascular Events among Patients with Acute Coronary Syndromes in a Commercial Health Plan Poster Session III
Conclusion: Our findings suggest that a modest 10% increase in anticoagulant use among patients with ACS would reduce mortality, MI, ST and related healthcare costs by 4%, 0.7%, and 3%, respectively. Addition of anticoagulation therapy potentially reduces the incidence of ACS-related mortality, MI, ST and associated healthcare costs to a commercial health plan, and benefits from anticoagulation use should be balanced against the risk of bleeding.
Source: Circulation: Cardiovascular Quality and Outcomes - May 15, 2013 Category: Cardiology Authors: Ogden, K., Patel, A. A., Mody, S. H., Veerman, M., Crivera, C., Quock, T. P. Tags: Poster Session III Source Type: research

Direct healthcare costs and cost-effectiveness of acute coronary syndromes secondary prevention with ticagrelor compared to clopidogrel - economic evaluation from the public payer's perspective in Poland based on the PLATO trial results.
CONCLUSIONS: In lifelong time horizon, which should be used in case of comparison of technologies with different impact on mortality, cost-effectiveness evaluation resulted in more favourable economic outcomes for ticagrelor than for generic clopidogrel with the cost per QALY well below recommended willingness to pay (WTP) threshold in Poland (24 965 PLN vs. 111 381 PLN). PMID: 24846362 [PubMed - as supplied by publisher]
Source: Polish Heart Journal - May 20, 2014 Category: Cardiology Authors: Pawęska J, Macioch T, Perkowski P, Budaj A, Niewada M Tags: Kardiol Pol Source Type: research